



**Adult CIRB – Early Phase Emphasis
Meeting Agenda**

**Tuesday, April 4, 2017
10:00 am – 12:20 pm (Eastern)**

I Initial Review

10067, A randomized phase 2 trial of cediranib and olaparib compared to bevacizumab in patients with recurrent glioblastoma who have not received prior VEGF therapy (Protocol Version Date 01/05/17)

II Study Chair Response to Tabling

10013, Randomized Phase 2 Study of Neoadjuvant Chemotherapy, Carboplatin and Paclitaxel, with or without Atezolizumab in Triple Negative Breast Cancer (TNBC) (Protocol Version Date 03/20/17)

III Amendment Review – Addendum 10 – MASTER only

EAY131, Molecular Analysis for Therapy Choice (MATCH) (Protocol Version Date 03/09/17)

IV Amendment Review

A071401, Phase II Trial Of SMO/AKT/NF2 Inhibitors in Progressive Meningiomas with SMO/AKT/NF2 Mutations (Protocol Version Date 03/01/17)

V Continuing Review

9944, Phase 2 Study of VX-970 (NSC# 780162) in Combination with gemcitabine versus gemcitabine alone in Subjects with Platinum-Resistant Recurrent Ovarian or Primary Peritoneal Fallopian Tube Cancer (Protocol Version Date 10/06/16)

VI Continuing Review

A091304, A Phase I /Randomized Phase II Study of MLN0128 (TAK-228) vs. Pazopanib In Patients With Locally Advanced/Unresectable And/Or Metastatic Sarcoma (Protocol Version Date 02/15/17)
